Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Four-week vs 6-week Therapy for Enterococcal Endocarditis
NCT05398289Phase 4Not yet recruiting
- Sponsor
- University of Magna Graecia
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
01
Overview
Phase 4, randomised, open-label trial of ampicillin, gentamicin, vancomycin, daptomycin and linezolid in infective endocarditis (IE) (2 arms), sponsored by University of Magna Graecia. Primary endpoint: Outcome at 60 days. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ampicillingentamicinvancomycindaptomycinlinezolid
03
Conditions
infective endocarditis (IE)
Beyond the preview
Go deeper on NCT05398289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398289.